Daily Morning Note – 17 January 2022

Welcome to our Daily Morning Note from our Research team!


Singapore shares displayed remarkable resilience on Friday, defying losses across most major regional bourses, which were rattled by hawkish “Fed speak” and a tepid overnight session in Wall Street. The key Straits Times Index jumped 24.67 points or 0.76 per cent to 3,281.97, pushing through its 2021 high of 3,273.54.

The Dow closed lower on Friday (Jan 14) with a big drag from financial stocks as investors were disappointed by fourth quarter results from big US banks, which cast a shadow over the earnings season kick-off. The Nasdaq and the S&P regained lost ground in afternoon trading to close higher. Meanwhile the consumer discretionary stocks put pressure on the indexes throughout the session after morning data showed a December decline in retail sales and a souring of consumer sentiment. The Dow Jones Industrial Average fell 201.81 points or 0.56 per cent to 35,911.81, the S&P 500 gained 3.82 points or 0.08 per cent to 4,662.85 and the Nasdaq Composite added 86.94 points or 0.59 per cent to 14,893.75. For the week, the S&P 500 fell 0.3 per cent while the Dow fell 0.9 per cent and the Nasdaq fell 0.3 per cent.

Stocks to watch: UOB



The Singapore Retailers Association (SRA) is calling for job support and hiring schemes to be extended and for rental relief to be legislated, even as the government plans to scale back Covid-19 support. Among a slew of suggestions in its Budget 2022 wishlist, SRA is also asking the government to remove mall capacity restrictions and give out one-off shopping vouchers of up to S$1,000 to “rejuvenate the retail scene”, one of the hardest-hit sectors during the pandemic. SRA said the removal of mall entry and dine-in restrictions can maximise benefits brought by Singapore’s Vaccinated Travel Lane (VTL) scheme and enhance the Republic’s attractiveness to visitors.

With recovering profitability and the lifting of dividend restrictions last year, the 3 local banks were positioned to surprise investors with higher dividend payouts for FY2021 and FY2022. Instead, UOB delivered a different sort of surprise last week. On Jan 14, the bank unveiled plans to acquire Citigroup’s consumer banking businesses in Indonesia, Malaysia, Thailand and Vietnam. The move will potentially put its capital to good use as the pandemic wanes and regional economic activity recovers over the next few years. It could also reposition UOB in the eyes of investors as a potent regional consumer banking play, and boost the performance of its shares over the next few years. Under the deal, UOB will pay a cash consideration equivalent to S$915 million plus the net asset value (NAV) of the consumer business as at completion of the transaction.

The private residential market is likely to start the year on a quiet note as developers wait until after Chinese New Year (Feb 1 and 2) to market their properties, analysts say. This seasonal lull also gives developers a chance to “wait and see” before making any major decisions in response to the recent round of property cooling measures. Since the curbs were introduced in mid-December last year, PropNex has observed a 20 to 30 per cent slowing in new home sales on average, compared to the weeks prior, said chief executive Ismail Gafoor. According to caveats lodged, developers sold 643 new homes in December 2021, excluding executive condominiums (ECs), down 58.4 per cent from November’s 1,547 units. “However, the slower sales are most likely due to seasonality and the holidays as buyers, sellers, or agents go on their year-end break. In our view, the dip in sales is not entirely a result of the cooling measures,” Gafoor said. Analysts added that they have not seen major announcements from project developers, such as launch delays or major price cuts.


Netflix has raised its monthly subscription price by US$1 to US$2 per month in the United States depending on the plan, the company said on Friday (Jan 14), to help pay for new programming to compete in the crowded streaming TV market. The standard plan, which allows for 2 simultaneous streams, now costs US$15.49 per month, up from US$13.99, in the United States. Prices also rose in Canada, where the standard plan climbed to C$16.49 (S$17.70) from C$14.99. Shares of Netflix gained nearly 3 per cent to US$533.84 on Nasdaq after Reuters broke the news of the price rises. They closed 1.3 per cent higher at US$525.69. The increases, the first in those markets since October 2020, took effect immediately for new customers. Existing members will see the new prices in the coming weeks when they receive their monthly bills.

Multiple states have begun investigating potential violations in how Facebook, now known as Meta Platforms, runs its virtual-reality Oculus business, according to 3 sources familiar with the matter. Two of the sources said the US Federal Trade Commission was also involved in the antitrust investigation. Meta did not immediately respond to a request for comment. New York, North Carolina and Tennessee were among the states involved in the inquiry, one source said. A group of almost 50 states also asked an appeals court on Friday (Jan 14) to reinstate their antitrust lawsuit, filed in December 2020, against Facebook. The inquiries into Facebook’s Oculus business are part of the larger probe, one of the sources said.

Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc’s consumer products division, Bloomberg reported on Sunday, citing people familiar with the matter. Unilever and GSK did not immediately respond to Reuters’requests for comment. The news came a day after GSK said it had rejected a £50-billion (S$92.13 billion) offer from Unilever for the consumer goods arm. GSK said it had received three bids from Unilever, the latest on Dec 20. Unilever could eventually sell some non-core assets from the GSK portfolio to buyers including private equity firms, which could help fund an acquisition, the Bloomberg report added.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR

Phillip Singapore Strategy – SPAC: Free lunch for the few

Analyst: Paul Chew

– Three special purpose acquisition companies (SPACs) will be launched on the SGX – Vertex Technology Acquisition Corp. (VTAC), Pegasus Asia (PA) and Novo Tellus Alpha Acquisition (NTAA, pending).

– The IPO offers are an attractive free lunch for investors. SPAC shares are 100% redeemable at S$5 offer price with free warrants thrown in with the shares. The public or retail offer is only 1.5 – 2.0% of the total issued shares.

– Apart from SPAC-ulating on the newsflow, we are cautious on SPACs post-IPO until valuations and ownership structures of the target company are determined.

United Overseas Bank Limited – Turning more competitive overnight

Recommendation: Accumulate (Maintained)

– UOB acquired Citigroup’s consumer banking franchise in Indonesia, Malaysia, Thailand and Vietnam for ~S$5bn.

– Maintain ACCUMULATE with a higher GGM TP of S$31.30, from S$29.00. We raise FY21e earnings by 3.8% as we increase NIM estimates for FY21e. We now assume 1.26x FY21e P/BV in our GGM valuation, up from 1.17x, as we raise our ROE estimates to 10.2%. Recovery path for UOB is on track. Potential upside surprise includes GP writebacks and special dividends.

Technical Pulse: Celanese Corp

Recommended: Technical Pulse; Analyst: Chua Wei Ren

Celanese Corp (US: CE) Technical price action indicates a bullish return

Buy spot: 173.53 Stop loss: 163.00 Take profit 1: 185.00 Take profit 2: 190.40

Technical Pulse: Duke Energy Corp

Recommended: Technical BUY; Analyst: Chua Wei Ren

Duke Energy Corp (US: CE) Technical price action indicates a bullish return

Buy stop: 105.00 Stop loss: 100.00 Take profit 1: 111.20 Take profit 2: 120.40

Technical Pulse: Genscript Biotech Corp

Recommended: Technical BUY; Analyst: Chua Wei Ren

Genscript Biotech (HKEX: 1548) Despite a stop-loss based on our report dated 25th November, we managed to achieve our first target profit in Dec 2021. Recent technicals have also shown a strong bullish continuation.

Buy spot: 32.00 Stop loss: 26.50 Take profit 1: 37.70 Take profit: 46.50

Technical Pulse: Sino Biopharmaceutical Ltd

Recommended: Technical BUY; Analyst: Chua Wei Ren

Sino Biopharmaceutical (HKEX: 1177) upside is returning based on technicals.

Buy spot: 6.15 Stop loss: 5.50 Take profit 1: 6.70 Take profit: 7.50

POEMS Podcast: Let the Money Talk

Recent Podcasts:

Bonus Track – CNY Edition

Daily Morning Note – January 14, 2022

Daily Morning Note – January 13, 2022

Visit www.stocksbnb.com to learn more!

Join our Phillip Securities Research Telegram channel for the latest update on our stock coverage!

Click here to join: https://t.me/stocksbnb

Webinar Of The Week

Weekly Market Outlook: Nasdaq 100, FAANGM, SPH REIT, SG Bank Monthly, SG Weekly

Date: 10 January 2022

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com